How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children
Antimicrob Agents Chemother. 2024 Apr 24:e0172923. doi: 10.1128/aac.01729-23. Online ahead of print.ABSTRACTStandard dosing could fail to achieve adequate systemic concentrations in ICU children or may lead to toxicity in children with acute kidney injury. The population pharmacokinetic analysis was used to simultaneously analyze all available data (plasma, prefilter, postfilter, effluent, and urine concentrations) and provide the pharmacokinetic characteristics of meropenem. The probability of target fT > MIC attainment, avoiding toxic levels, during the entire dosing interval was estimated by simulation of different i...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Laura Butrague ño-Laiseca I ñaki F Troconiz Santiago Grau Nuria Campillo Bel én Padilla Sarah Nicole Fern ández Mar ía Slöcker Laura Herrera Mar ía José Santiago Source Type: research

< em > In vitro < /em > activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM)
Antimicrob Agents Chemother. 2024 Apr 24:e0168423. doi: 10.1128/aac.01684-23. Online ahead of print.ABSTRACTNovel antimicrobials are needed to treat rising nontuberculous mycobacteria (NTM) infections. Using standard broth microdilution methods, 68 NTM isolates were tested against gepotidacin, a new, first-in-class, oral triazaacenaphthylene bacterial topoisomerase inhibitor. MICs varied (0.25 to >64 µg/mL) with the lowest being M. fortuitum complex (0.25-8 µg/mL), M. mucogenicum complex (1-2 µg/mL), M. kansasii (0.25-8 µg/mL), and M. marinum (4-16 µg/mL). Testing greater numbers of some species is suggested to bet...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Barbara A Brown-Elliott Georgie Bush M Dolores Hughes Eliana Rodriguez Chase A Weikel Sharon B Min Richard J Wallace Source Type: research

Loureirin A is a narrow-spectrum antimicrobial agent against < em > Helicobacter pylori < /em >
In this study, loureirin A (LrA), a traditional Chinese medicine monomer extracted from Sanguis Draconis flavones, was found to possess specific antibacterial activity against H. pylori without the bacteria displaying a tendency to develop resistance in vitro. LrA demonstrated a synergistic or additive effect when combined with omeprazole (a proton pump inhibitor) against H. pylori. The combination of LrA and omeprazole showed promising anti-H. pylori potential, exhibiting notable in vivo efficacy comparable to standard triple therapy in mouse models infected with both drug-sensitive and drug-resistant H. pylori strains. M...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Qian Tong Chengqiang Yin Xudong Hang Yuefan Bai Chongwen Zhang Jingcheng Xu Yan Huang Yixin Ge Tianyu Chen Liping Zeng Jia Jia Hongkai Bi Source Type: research

How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children
Antimicrob Agents Chemother. 2024 Apr 24:e0172923. doi: 10.1128/aac.01729-23. Online ahead of print.ABSTRACTStandard dosing could fail to achieve adequate systemic concentrations in ICU children or may lead to toxicity in children with acute kidney injury. The population pharmacokinetic analysis was used to simultaneously analyze all available data (plasma, prefilter, postfilter, effluent, and urine concentrations) and provide the pharmacokinetic characteristics of meropenem. The probability of target fT > MIC attainment, avoiding toxic levels, during the entire dosing interval was estimated by simulation of different i...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Laura Butrague ño-Laiseca I ñaki F Troconiz Santiago Grau Nuria Campillo Bel én Padilla Sarah Nicole Fern ández Mar ía Slöcker Laura Herrera Mar ía José Santiago Source Type: research

< em > In vitro < /em > activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM)
Antimicrob Agents Chemother. 2024 Apr 24:e0168423. doi: 10.1128/aac.01684-23. Online ahead of print.ABSTRACTNovel antimicrobials are needed to treat rising nontuberculous mycobacteria (NTM) infections. Using standard broth microdilution methods, 68 NTM isolates were tested against gepotidacin, a new, first-in-class, oral triazaacenaphthylene bacterial topoisomerase inhibitor. MICs varied (0.25 to >64 µg/mL) with the lowest being M. fortuitum complex (0.25-8 µg/mL), M. mucogenicum complex (1-2 µg/mL), M. kansasii (0.25-8 µg/mL), and M. marinum (4-16 µg/mL). Testing greater numbers of some species is suggested to bet...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Barbara A Brown-Elliott Georgie Bush M Dolores Hughes Eliana Rodriguez Chase A Weikel Sharon B Min Richard J Wallace Source Type: research

Loureirin A is a narrow-spectrum antimicrobial agent against < em > Helicobacter pylori < /em >
In this study, loureirin A (LrA), a traditional Chinese medicine monomer extracted from Sanguis Draconis flavones, was found to possess specific antibacterial activity against H. pylori without the bacteria displaying a tendency to develop resistance in vitro. LrA demonstrated a synergistic or additive effect when combined with omeprazole (a proton pump inhibitor) against H. pylori. The combination of LrA and omeprazole showed promising anti-H. pylori potential, exhibiting notable in vivo efficacy comparable to standard triple therapy in mouse models infected with both drug-sensitive and drug-resistant H. pylori strains. M...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Qian Tong Chengqiang Yin Xudong Hang Yuefan Bai Chongwen Zhang Jingcheng Xu Yan Huang Yixin Ge Tianyu Chen Liping Zeng Jia Jia Hongkai Bi Source Type: research

How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children
Antimicrob Agents Chemother. 2024 Apr 24:e0172923. doi: 10.1128/aac.01729-23. Online ahead of print.ABSTRACTStandard dosing could fail to achieve adequate systemic concentrations in ICU children or may lead to toxicity in children with acute kidney injury. The population pharmacokinetic analysis was used to simultaneously analyze all available data (plasma, prefilter, postfilter, effluent, and urine concentrations) and provide the pharmacokinetic characteristics of meropenem. The probability of target fT > MIC attainment, avoiding toxic levels, during the entire dosing interval was estimated by simulation of different i...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Laura Butrague ño-Laiseca I ñaki F Troconiz Santiago Grau Nuria Campillo Bel én Padilla Sarah Nicole Fern ández Mar ía Slöcker Laura Herrera Mar ía José Santiago Source Type: research

< em > In vitro < /em > activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM)
Antimicrob Agents Chemother. 2024 Apr 24:e0168423. doi: 10.1128/aac.01684-23. Online ahead of print.ABSTRACTNovel antimicrobials are needed to treat rising nontuberculous mycobacteria (NTM) infections. Using standard broth microdilution methods, 68 NTM isolates were tested against gepotidacin, a new, first-in-class, oral triazaacenaphthylene bacterial topoisomerase inhibitor. MICs varied (0.25 to >64 µg/mL) with the lowest being M. fortuitum complex (0.25-8 µg/mL), M. mucogenicum complex (1-2 µg/mL), M. kansasii (0.25-8 µg/mL), and M. marinum (4-16 µg/mL). Testing greater numbers of some species is suggested to bet...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Barbara A Brown-Elliott Georgie Bush M Dolores Hughes Eliana Rodriguez Chase A Weikel Sharon B Min Richard J Wallace Source Type: research

Loureirin A is a narrow-spectrum antimicrobial agent against < em > Helicobacter pylori < /em >
In this study, loureirin A (LrA), a traditional Chinese medicine monomer extracted from Sanguis Draconis flavones, was found to possess specific antibacterial activity against H. pylori without the bacteria displaying a tendency to develop resistance in vitro. LrA demonstrated a synergistic or additive effect when combined with omeprazole (a proton pump inhibitor) against H. pylori. The combination of LrA and omeprazole showed promising anti-H. pylori potential, exhibiting notable in vivo efficacy comparable to standard triple therapy in mouse models infected with both drug-sensitive and drug-resistant H. pylori strains. M...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Qian Tong Chengqiang Yin Xudong Hang Yuefan Bai Chongwen Zhang Jingcheng Xu Yan Huang Yixin Ge Tianyu Chen Liping Zeng Jia Jia Hongkai Bi Source Type: research

How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children
Antimicrob Agents Chemother. 2024 Apr 24:e0172923. doi: 10.1128/aac.01729-23. Online ahead of print.ABSTRACTStandard dosing could fail to achieve adequate systemic concentrations in ICU children or may lead to toxicity in children with acute kidney injury. The population pharmacokinetic analysis was used to simultaneously analyze all available data (plasma, prefilter, postfilter, effluent, and urine concentrations) and provide the pharmacokinetic characteristics of meropenem. The probability of target fT > MIC attainment, avoiding toxic levels, during the entire dosing interval was estimated by simulation of different i...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Laura Butrague ño-Laiseca I ñaki F Troconiz Santiago Grau Nuria Campillo Bel én Padilla Sarah Nicole Fern ández Mar ía Slöcker Laura Herrera Mar ía José Santiago Source Type: research

< em > In vitro < /em > activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM)
Antimicrob Agents Chemother. 2024 Apr 24:e0168423. doi: 10.1128/aac.01684-23. Online ahead of print.ABSTRACTNovel antimicrobials are needed to treat rising nontuberculous mycobacteria (NTM) infections. Using standard broth microdilution methods, 68 NTM isolates were tested against gepotidacin, a new, first-in-class, oral triazaacenaphthylene bacterial topoisomerase inhibitor. MICs varied (0.25 to >64 µg/mL) with the lowest being M. fortuitum complex (0.25-8 µg/mL), M. mucogenicum complex (1-2 µg/mL), M. kansasii (0.25-8 µg/mL), and M. marinum (4-16 µg/mL). Testing greater numbers of some species is suggested to bet...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Barbara A Brown-Elliott Georgie Bush M Dolores Hughes Eliana Rodriguez Chase A Weikel Sharon B Min Richard J Wallace Source Type: research

Loureirin A is a narrow-spectrum antimicrobial agent against < em > Helicobacter pylori < /em >
In this study, loureirin A (LrA), a traditional Chinese medicine monomer extracted from Sanguis Draconis flavones, was found to possess specific antibacterial activity against H. pylori without the bacteria displaying a tendency to develop resistance in vitro. LrA demonstrated a synergistic or additive effect when combined with omeprazole (a proton pump inhibitor) against H. pylori. The combination of LrA and omeprazole showed promising anti-H. pylori potential, exhibiting notable in vivo efficacy comparable to standard triple therapy in mouse models infected with both drug-sensitive and drug-resistant H. pylori strains. M...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Qian Tong Chengqiang Yin Xudong Hang Yuefan Bai Chongwen Zhang Jingcheng Xu Yan Huang Yixin Ge Tianyu Chen Liping Zeng Jia Jia Hongkai Bi Source Type: research

How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children
Antimicrob Agents Chemother. 2024 Apr 24:e0172923. doi: 10.1128/aac.01729-23. Online ahead of print.ABSTRACTStandard dosing could fail to achieve adequate systemic concentrations in ICU children or may lead to toxicity in children with acute kidney injury. The population pharmacokinetic analysis was used to simultaneously analyze all available data (plasma, prefilter, postfilter, effluent, and urine concentrations) and provide the pharmacokinetic characteristics of meropenem. The probability of target fT > MIC attainment, avoiding toxic levels, during the entire dosing interval was estimated by simulation of different i...
Source: Antimicrobial Agents and Chemotherapy - April 24, 2024 Category: Microbiology Authors: Laura Butrague ño-Laiseca I ñaki F Troconiz Santiago Grau Nuria Campillo Bel én Padilla Sarah Nicole Fern ández Mar ía Slöcker Laura Herrera Mar ía José Santiago Source Type: research

Altered serine metabolism promotes drug tolerance in < em > Mycobacterium abscessus < /em > via a WhiB7-mediated adaptive stress response
Antimicrob Agents Chemother. 2024 Apr 23:e0145623. doi: 10.1128/aac.01456-23. Online ahead of print.ABSTRACTMycobacterium abscessus is an emerging opportunistic pathogen responsible for chronic lung diseases, especially in patients with cystic fibrosis. Treatment failure of M. abscessus infections is primarily associated with intrinsic or acquired antibiotic resistance. However, there is growing evidence that antibiotic tolerance, i.e., the ability of bacteria to transiently survive exposure to bactericidal antibiotics through physiological adaptations, contributes to the relapse of chronic infections and the emergence of ...
Source: Antimicrobial Agents and Chemotherapy - April 23, 2024 Category: Microbiology Authors: C élia Bernard Yi Liu G érald Larrouy-Maumus Christophe Guilhot Kaymeuang Cam Christian Chalut Source Type: research

Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects
This study was registered at the Chinese Clinical Trial Registry under identifier ChiCTR2200056692.PMID:38647294 | DOI:10.1128/aac.01563-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - April 22, 2024 Category: Microbiology Authors: Size Li Xu Zhu Guoying Cao Jufang Shen Xu Zhu Jicheng Yu Xiaojie Wu Jufang Wu Haijing Yang Nanyang Li Yingying Hu Jingjing Wang Haihui Huang Jing Zhang Source Type: research